Acceleron’s GDF Therapies: Just Different Enough?
This article was originally published in The Pink Sheet Daily
EPO-like, Avastin-like portfolio is designed for “enormous” indications, but piggy-back possibilities are too early to forecast.
You may also be interested in...
Private/public infusion will see synthetic ESA through trials and approval.
Novel RANK ligand inhibitor could have Oct. 19, 2009, PDUFA date.
Takeda and Affymax revise Hematide program to stop development for chemotherapy-induced anemia and focus on anemia related to chronic kidney disease.